Stockholm, Sweden

ESTRO 2026

Session

Sunday
May 17
10:30 - 11:30
K2
Urological cancers 3
Ioan Flavius Coser, Romania;
Stefano Maria Magrini, Italy
Poster Discussions
Clinical
10:30 - 11:30
Three-fractions Linac-Based Prostate SBRT Using 4D Transperineal Ultrasound Monitoring: Preliminary Clinical Outcomes and Analysis of Motion Patterns
Federica Ferrario, Italy
-233
10:30 - 11:30
Post-treatment ADC predicts long-term outcomes after definitive radiotherapy for prostate cancer with or without focal boost
Cem Onal, Turkey
-468
10:30 - 11:30
Safety of Elective Pelvic Nodal Irradiation in High-Risk Post-Prostatectomy Patients: A Subgroup Analysis from POPART (PELVART) Cohort
Federica Ferrario, Italy
-1142
10:30 - 11:30
Phase 1 Study of Localized Antiandrogen Therapy Using Biolen® (Bicalutamide) Implants with Radiotherapy for Localized Prostate Cancer
Deborah Citrin, USA
-4509
10:30 - 11:30
Patient- and Clinician-Reported adverse events in primary Prostate Only and Whole Pelvis Moderately Hypofractionated Prostate Radiotherapy
Leo Andexlinger, Austria
-589
10:30 - 11:30
Reirradiation of local recurrences of prostate cancer: PROSTARE (PROstate cancer STereotActic REirradiation) early safety analysis of a phase 2 study
Wojciech Majewski, Poland
-1850
10:30 - 11:30
Predictive value of the circulating T-cell receptor repertoire in oligorecurrent prostate cancer treated with SBRT: results from a prospective trial
Fabio Matrone, Italy
-2331
10:30 - 11:30
Prognostic Factors for Recurrence and Survival in Bladder-Preserving Therapy for Muscle-Invasive Bladder Cancer
Felipe Couñago Lorenzo, Spain
-2078
10:30 - 11:30
Impact of Medical Operability For Primary Renal Cell Carcinoma After Stereotactic Ablative Radiotherapy
Vivian Tan, Canada
-1690
10:30 - 11:30
Definitive Radiotherapy for Stage T4 Non-Metastatic Prostate Cancer: Long-Term Outcomes from a multicentric collaboration
Vasanthapriya Subramani , India
-2338